Relationships between epistaxis, migraines, and triggers in hereditary hemorrhagic telangiectasia

Laryngoscope

Volumn 124, Issue 7, 2014, Pages 1521-1528

  Elphick, Amy ^a,b,c   Shovlin, Claire L ^a,b  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

diet; Epistaxis; lifestyle; migraines; sleep

Indexed keywords

ALCOHOL; CAFFEINE; IRON;

ADULT; ADVERTIZING; AGED; ARTICLE; AUTONOMIC DYSFUNCTION; BLOOD TRANSFUSION; BRAIN ARTERIOVENOUS MALFORMATION; CACAO; CHEESE; CLINICAL FEATURE; CLINICAL PRACTICE; CONTROLLED STUDY; DIETARY INTAKE; DISEASE ASSOCIATION; EPISTAXIS; FEMALE; HEADACHE; HUMAN; IRON DEFICIENCY ANEMIA; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MENSTRUAL CYCLE; MIGRAINE; MULTICENTER STUDY; NEUROLOGIC DISEASE; PHYSICAL ACTIVITY; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; PULMONARY ARTERIOVENOUS FISTULA; QUESTIONNAIRE; RATING SCALE; RENDU OSLER WEBER DISEASE; RISK FACTOR; SLEEP DEPRIVATION; STRESS; UNITED KINGDOM;

DIET; EPISTAXIS; LIFESTYLE; MIGRAINES; SLEEP;

ADULT; AGED; AGED, 80 AND OVER; EPISTAXIS; FEMALE; GREAT BRITAIN; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MIGRAINE DISORDERS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; RISK FACTORS; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; YOUNG ADULT;

EID: 84903163080     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.24526     Document Type: Article

References (71)

1. Shovlin CL,. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev 2010; 24: 203-219.
2. Kjeldsen AD, Vase P, Green A,. Hereditary haemorrhagic telangiectasia: a population-based study of prevalence and mortality in Danish patients. J Intern Med 1999; 245: 31-39. (Pubitemid 29049140)
3. Dakeishi M, Shioya T, Wada Y, et al. Genetic epidemiology of hereditary hemorrhagic telangiectasia in a local community in the northern part of Japan. Hum Mutat 2002; 19: 140-148. (Pubitemid 34121805)
4. Abdalla SA, Letarte M,. Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease. J Med Genet 2006; 43: 97-110. (Pubitemid 43262964)
5. Park S, Wankhede M, Lee Y, et al. Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia. J Clin Invest 2009; 119: 3487-3496.
6. Lebrin F, Srun S, Raymond K, et al. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med 2010; 16: 420-428.
7. McDonald J, Bayrak-Toydemir P, Pyeritz RE,. Hereditary hemorrhagic telangiectasia: an overview of diagnosis, management, and pathogenesis. Genet Med 2011; 13: 607-616.
8. AAssar OS, Friedman CM, White RI Jr,. The natural history of epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 1991; 101: 977-980.
9. Folz BJ, Tennie J, Lippert BM, Werner JA,. Natural history and control of epistaxis in a group of German patients with Rendu-Osler-Weber disease. Rhinology 2005; 43: 40-46.
10. Silva BM, Hosman AE, Devlin HL, Shovlin CL,. Lifestyle and dietary influences on nosebleed severity in hereditary hemorrhagic telangiectasia. Laryngoscope 2013; 123: 1092-1099.
11. Plauchu H, de Chadarevian JP, Bideau A, Robert JM,. Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 1989; 32: 291-297. (Pubitemid 19146524)
12. Richer SL, Geisthoff UW, Livada N, et al. The Young's procedure for severe epistaxis from hereditary hemorrhagic telangiectasia. Am J Rhinol Allergy 2012; 26: 401-404.
13. Faughnan ME, Palda VA, Garcia-Tsao G, et al. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet 2011; 48: 73-87.
14. Finnamore H, Le Couteur J, Hickson M, Busbridge M, Whelan K, Shovlin CL,. Hemorrhage-adjusted iron requirements, hematinics and hepcidin define hereditary haemorrhagic telangiectasia as a model of hemorrhagic iron deficiency. PLoS One 2013; 8: e76516.
15. Ingrand I, Ingrand P, Gilbert-Dussardier B, et al. Altered quality of life in Rendu-Osler-Weber disease related to recurrent epistaxis. Rhinology 2011; 49: 155-162.
16. Loaec M, Moriniere S, Hitier M, Ferrant O, Plauchu H, Babin E,. Psychosocial quality of life in hereditary haemorrhagic telangiectasia patients. Rhinology 2011; 49: 164-167.
17. Mahoney EJ, Shapshay SM,. Nd-YAG laser photocoagulation for epistaxis associated with hereditary hemorrhagic telangiectasia. Laryngoscope 2005; 115: 373-375. (Pubitemid 40216723)
18. Harvey RJ, Kanagalingam J, Lund VJ,. The impact of septodermoplasty and potassium-titanyl-phosphate (KTP) laser therapy in the treatment of hereditary hemorrhagic telangiectasia-related epistaxis. Am J Rhinol 2008; 22: 182-187. (Pubitemid 351570562)
19. Yaniv E, Preis M, Hadar T, Shvero J, Haddad M,. Antiestrogen therapy for hereditary hemorrhagic telangiectasia: a double-blind placebo-controlled clinical trial. Laryngoscope 2009; 119: 284-288.
20. Karnezis TT, Davidson TM,. Efficacy of intranasal bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope 2011; 121: 636-638.
21. Brinkerhoff BT, Choong NW, Treisman JS, Poetker DM,. Intravenous and topical intranasal bevacizumab (Avastin) in hereditary hemorrhagic telangiectasia. Am J Otolaryngol 2012; 33: 349-351.
22. de Gussem E, Snijder R, Disch F, Zanen P, Westermann C, Mager J,. The effect of N-acetylcysteine on epistaxis and quality of life in patients with HHT: a pilot study. Rhinology 2009; 47: 85-88.
23. Lund V, Howard D,. A treatment algorithm for the management of epistaxis in hereditary haemorrhagic telangiectasia. Am J Rhinol 1999; 13: 319-322.
24. Stewart WF, Shechter A, Rasmussen BK,. Migraine prevalence. A review of population-based studies. Neurology 1994; 44: S17-S23.
25. Hodgson CH, Burchell HB, Good CA, Clagett OT,. Hereditary hemorrhagic telangiectasia and pulmonary arteriovenous fistula. Study of a large family. New Engl J Med 1959; 261: 625-636.
26. Steele JG, Nath PU, Burn J, Porteous ME,. An association between migrainous aura and hereditary haemorrhagic telangiectasia. Headache 1993; 33: 145-148. (Pubitemid 23110624)
27. Marziniak M, Jung A, Guralnik V, Evers S, Prudlo J, Geisthoff UW,. An association of migraine with hereditary haemorrhagic telangiectasia independently of pulmonary right-to-left shunts. Cephalalgia 2009; 29: 76-81.
28. Shovlin CL, Jackson JE,. Pulmonary arteriovenous malformations and other vascular abnormalities. In:, Mason RJ, Broaddus VC, Martin T, et al., eds. Murray and Nadel's Textbook of Respiratory Medicine. 5th ed. Philadelphia, PA: Elsevier-Saunders; 2010: 1261-1282.
29. Cottin V, Chinet T, Lavole A, et al. Pulmonary arteriovenous malformations in hereditary hemorrhagic telangiectasia: a series of 126 patients. Medicine (Baltimore) 2007; 86: 1-17. (Pubitemid 46104915)
30. van Gent MW, Post MC, Snijder RJ, Westermann CJ, Plokker HW, Mager JJ,. Real prevalence of pulmonary right-to-left shunt according to genotype in patients with hereditary hemorrhagic telangiectasia: a transthoracic contrast echocardiography study. Chest 2010; 138: 833-839.
31. Post MC, Letteboer TG, Mager JJ, Plokker TH, Kelder JC, Westermann CJ,. A pulmonary right-to-left shunt in patients with hereditary haemorrhagic telangiectasia is associated with an increased prevalence of migraine. Chest 2005; 128: 2485-2489. (Pubitemid 41507598)
32. Thenganatt J, Schneiderman J, Hyland RH, Edmeads J, Mandzia JL, Faughnan ME,. Migraines linked to intrapulmonary right-to-left shunt. Headache 2006; 46: 439-443.
33. Post MC, van Gent MW, Plokker HW, et al. Pulmonary arteriovenous malformations associated with migraine with aura. Eur Respir J 2009; 34: 882-887.
34. Post MC, Thijs V, Schonewille WJ, et al. Embolization of pulmonary arteriovenous malformations and decrease in prevalence of migraine. Neurology 2006; 66: 202-205. (Pubitemid 43970154)
35. Devlin HL, Hosman AE, Shovlin CL,. Antiplatelet and anticoagulant agents in hereditary hemorrhagic telangiectasia. N Engl J Med 2013; 368: 876-878.
36. Hosman AE, Devlin HL, Silva BM, Elphick AH, Shovlin CL,. Specific cancer rates may differ in patients with hereditary haemorrhagic telangiectasia compared to controls. Orphanet Journal of Rare Diseases. 2013, 8:195. DOI: 10.1186/1750-1172-8-195
37. HHT Foundation International, Inc. Available at: www.hht.org Accessed September 30, 2013.
38. Shovlin CL, Guttmacher AE, Buscarini E, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000; 91: 66-67. (Pubitemid 30127562)
39. van Gent MW, Velthuis S, Post MC, et al. Hereditary hemorrhagic telangiectasia: how accurate are the clinical criteria? Am J Med Genet A 2013; 161: 461-466.
40. International Headache Society. IHS classification ICHD-2. Available at: http://ihs-classification.org/en/, first accessed for this study 25 March 2013. Reaccessed 20 December 2013.
41. Migraine Trust. Diagnosing migraine. Available at: http://www. migrainetrust.org/health-professionals/diagnosing-migraine, first accessed for this study 25 March 2013. Reaccessed 20 December 2013.
42. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders. 2nd ed. Cephalalgia 2004; 24 (suppl 1): 9-160.
43. Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E,. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012; 78: 1337-1345.
44. Koch HJ, Escher GC, Lewis JS,. Hormonal management of hereditary hemorrhagic telangiectasia. J Am Med Soc 1952; 149: 1376-1380.
45. Harrison DFN,. Familial haemorrhagic telangiectasia. Q J Med 1964; 129: 25-38.
46. Harris PWR,. Hereditary haemorrhagic telangiectasia and oral contraceptives. Lancet 1970; 1: 615-616.
47. Flessa HC, Glueck HI,. Hereditary hemorrhagic telangiecatsia (Osler-Weber-Rendu disease). Management of epistaxis in nine patients using systemic hormone therapy. Arch Otolaryngol 1977; 103: 148-151. (Pubitemid 8057682)
48. van Cutsem E, Rutgeerts P, Vantrappen G,. Treatment of bleeding gastrointestinal vascular malformations with oestrogen-progesterone. Lancet 1990; 335: 953-955. (Pubitemid 20134976)
49. Yaniv E, Preis M, Hadar T, Shvero J, Haddad M,. Antiestrogen therapy for hereditary hemorrhagic telangiectasia: a double-blind placebo-controlled clinical trial. Laryngoscope 2009; 119: 284-288.
50. Albinana V, Bernabeu-Herrero ME, Zarrabeitia R, Bernabeu C, Botella LM,. Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): effects of raloxifene on endoglin and ALK1 expression in endothelial cells. Thromb Haemost 2010; 103: 525-534.
51. Vecchia D, Pietrobon D,. Migraine: a disorder of brain excitatory-inhibitory balance? Trends Neurosci 2012; 35: 507-520.
52. van den Maagdenberg AM, Pietrobon D, Pizzorusso T, et al. A Cacna1a knockin migraine mouse model with increased susceptibility to cortical spreading depression. Neuron 2004; 41: 701-710. (Pubitemid 38326833)
53. Eikermann-Haerter K, Moskowitz MA,. Animal models of migraine headache and aura. Curr Opin Neurol 2008; 21: 294-300. (Pubitemid 351653979)
54. Bergerot A, Holland PR, Akerman S, et al. Animal models of migraine: looking at the component parts of a complex disorder. Eur J Neurosci 2006; 24: 1517-1534. (Pubitemid 44429881)
55. Franceschini A, Vilotti S, Ferrari MD, van den Maagdenberg AM, Nistri A, Fabbretti E,. TNFα levels and macrophages expression reflect an inflammatory potential of trigeminal ganglia in a mouse model of familial hemiplegic migraine. PLoS One 2013; 8: e52394.
56. Jen JC, Kim GW, Dudding KA, Baloh RW,. No mutations in CACNA1A and ATP1A2 in probands with common types of migraine. Arch Neurol 2004; 61: 926-928. (Pubitemid 38747334)
57. Charles AC, Baca SM,. Cortical spreading depression and migraine. Nat Rev Neurol 2013; 9: 637-644.
58. Chasman DI, Schurks M, Anttila V, et al. Genome-wide association study reveals three susceptibility loci for common migraine in the general population. Nat Genet 2011; 43: 695-698.
59. Freilinger T, Anttila V, de Vries B, et al. Genome-wide association analysis identifies susceptibility loci for migraine without aura. Nat Genet 2012; 44: 777-782.
60. Law C, Bunyan D, Castle B, et al. Clinical features in a family with an R460H mutation in transforming growth factor beta receptor 2 gene. J Med Genet 2006; 43: 908-916. (Pubitemid 46080187)
61. Ishizaki K, Takeshima T, Fukuhara Y, et al. Increased plasma transforming growth factor-beta1 in migraine. Headache 2005; 45: 1224-1228. (Pubitemid 350004912)
62. Guzel I, Tasdemir N, Celik Y,. Evaluation of serum transforming growth factor β1 and C-reactive protein levels in migraine patients. Neurol Neurochir Pol 2013; 47: 357-362.
63. Sadick H, Riedel F, Naim R, et al. Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica 2005; 90: 818-828.
64. Letarte M, McDonald ML, Li C, et al. Reduced endothelial secretion and plasma levels of transforming growth factor-beta1 in patients with hereditary hemorrhagic telangiectasia type 1. Cardiovasc Res 2005; 68: 155-164. (Pubitemid 41253566)
65. Vernieri F, Moro L, Altamura C, et al. Patients with migraine with aura have increased flow mediated dilation. BMC Neurol 2010; 10: 18.
66. Hajjar I, Zhao P, Alsop D, Novak V,. Hypertension and cerebral vasoreactivity: a continuous arterial spin labeling magnetic resonance imaging study. Hypertension 2010; 56: 859-864.
67. Chang TY, Kuan WC, Huang KL, et al. Heterogeneous cerebral vasoreactivity dynamics in patients with carotid stenosis. PLoS One 2013; 8: e76072.
68. Deplanque D, Lavallee PC, Labreuche J, et al. Cerebral and extracerebral vasoreactivity in symptomatic lacunar stroke patients: a case-control study. Int J Stroke 2013; 8: 413-421.
69. Fujiwara Y, Mizuno T, Okuyama C, et al. Simultaneous impairment of intracranial and peripheral artery vasoreactivity in CADASIL patients. Cerebrovasc Dis 2012; 33: 128-134.
70. Krejza J, Rudzinski W, Arkuszewski M, Onuoha O, Melhem ER,. Cerebrovascular reactivity across the menstrual cycle in young healthy women. Neuroradiol J 2013; 26: 413-419.
71. Saban Y, Amodeo CA, Bouaziz D, Polselli R,. Nasal arterial vasculature: medical and surgical applications. Arch Facial Plast Surg 2012; 14: 429-436.